Amyotrophic Lateral Sclerosis (ALS) / Lou Gehrig's disease

Product description

The present Competitive Intelligence Report about Amyotrophic Lateral Sclerosis (ALS) / Lou Gehrig’s disease provides a competitor evaluation about new treatments in the R&D pipeline of amyotrophic lateral sclerosis (ALS) / Lou Gehrig’s disease as of March 2009.

Amyotrophic lateral sclerosis (ALS, also called Lou Gehrig's disease) is a rapidly progressing, motor neuron disease characterized by the gradual degeneration and death of motor neurons. When muscles in the diaphragm and chest wall fail, patients lose the ability to breathe without ventilatory support. Most people with ALS die from respiratory failure. Approximately 120, 000 new cases are diagnosed each year. No cure has yet been found for ALS. There is one FDA approved drug, riluzole, that modestly slows the progression of ALS.

Quite a number of approaches to treat ALS are being investigated in clinical trials: of the 20 different approaches, the majority (16) are small molecule based treatments, followed by biologics such as proteins, peptides and antibodies and more recently cell-based therapies have emerged for clinical testing. Among the targets being clinically tested are glutamate based therapies, antioxidants, cellular energy regulators, immunomodulators and neuroprotective/neurotrophic therapies. Biologic therapies study the neuroprotective effects of VEGF or are directed at the misfolded superoxide dismutase (SOD-1) among other approaches. Cellular therapies intent to induce regeneration of neuronal cells and tissues.

The report includes a compilation of current active projects in research and development of small molecules, antibodies, proteins, peptides, vaccines and other biologics including cells for treatment of amyotrophic lateral sclerosis (ALS). In addition, the report lists company-specific R&D pipelines of new treatments of ALS. Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.
  

Index

• Small Molecule Approaches for Treatment of ALS
• Biologics for Treatment of ALS
• Cellular Approaches for ALS Therapy
• Corporate R&D Pipelines of New Treatments for ALS
• About La Merie
  

About Competitor Analysis Series

The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced. Competitor analysis reports can be purchased as individual products or obtained by subscribing to R&D Pipeline News. R&D Pipeline News is published weekly 50-times a year and each issue contains at least two competitor evaluations. Individual products from the Competitor Analysis Series and R&D Pipeline News are independently elaborated by analysts of La Merie Business Intelligence and distributed by PipelineReview.com.